Wysa
Wysa makes an AI chatbot for mental health, now buying clinics to add human care.
On the record
Checkpoint: Deadline for Series C at flat-or-up valuation, or clear disclosure that clinical services exceed 40% of revenue
The call
Wysa is racing to turn a commoditizing chatbot into a clinical services company before its funding runway and category both run out.
Wysa started as an AI chatbot for mental health support, but that basic chatbot approach is now being replaced by more powerful AI systems like ChatGPT and Claude, which do the same thing better for free. The company is trying to survive by buying real therapist practices and building an insurance billing business instead, but this new direction is brand new and unproven. What matters most: whether Wysa can raise a major funding round in the next 18 months to prove its therapist-plus-billing model works, because four years of relying only on grants and not selling stock signals the company may be running out of money to compete against bigger health insurers like UnitedHealth that already own therapy services and can copy this playbook faster.
Why
01
AI pressure: General-purpose LLMs like GPT-4, Claude, Gemini. Free-form chatbots now match scripted CBT bots; Woebot cited this exact pressure when it shut down in June 2025. Could AI do the core job? Yes, likely.
02
Bigger players: UnitedHealth and large payers (Aetna, Spring Health, Lyra, Modern Health). UnitedHealth already absorbed Sanvello in-house and shut its consumer app in 2025, showing payers can build or buy this themselves. Could a giant copy it? Yes, easily.
03
What protects it. Enterprise contracts with NHS and Singapore MOH plus new licensed clinical services from April Health and Kins acquisitions.
What would change this call
Wysa announces a priced Series C round by mid-2027. Would show investor confidence in the services pivot beyond grant funding.
Wysa discloses April Health plus Kins revenue share of total ARR. Would show whether the services moat is actually replacing chatbot revenue.
Wysa converts FDA Breakthrough Designation into full marketing authorization. Would validate the regulatory moat rather than leaving it as an unproven claim.
Wysa discloses April Health plus Kins revenue share of total ARR. Would show whether the services moat is actually replacing chatbot revenue.
Wysa converts FDA Breakthrough Designation into full marketing authorization. Would validate the regulatory moat rather than leaving it as an unproven claim.
Key numbers
- No priced equity round since $20M Series B
- Estimated FY2024 revenue $4.68M
- Two acquisitions (April Health, Kins) in six months
Named risks
- Core chatbot product category commoditized by frontier LLMs, as proven by Woebot's June 2025 shutdown.
- No priced equity round since July 2022, relying on grants, raising funding runway concerns.
- Two acquisitions within six months (April Health, Kins) create integration and clinical-liability complexity.
- FDA Breakthrough Device Designation from 2022 has not converted to full marketing authorization.
- Incumbent payers like UnitedHealth can build or buy equivalent in-house digital mental health tools.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Woebot Health | gaining on | Woebot shut down consumer app June 30, 2025 citing LLM disruption, leaving Wysa among fewer direct peers |
| UnitedHealth (Sanvello) | losing to | UnitedHealth absorbed rival Sanvello in-house, discontinuing its consumer app in 2025 |
| Frontier LLMs (GPT-4, Claude, Gemini) | losing to | General-purpose LLMs commoditized scripted CBT chatbots, per Woebot's July 2025 shutdown explanation |
| Spring Health, Lyra, Modern Health | contesting | Named as competing large payer/EAP digital mental health players in same enterprise market as of 2025-2026 |
Questions people ask
- Is Wysa profitable?
- No public profitability data exists. Wysa has raised no priced equity since its July 2022 Series B ($20M), relying since then on grants like Wellcome Trust and NIH funding, which suggests it is not generating self-sustaining profit as of 2026.
- Could AI replace Wysa's chatbot?
- Possibly. Wysa's core scripted CBT chatbot is the exact category frontier LLMs like GPT-4 have commoditized. Its closest peer, Woebot, shut down its consumer app on June 30, 2025, citing general-purpose LLMs making its approach undifferentiated.
- Who owns Wysa?
- Wysa is privately held, founded in 2015 by Jo Aggarwal and Ramakant Vempati as a Touchkin eServices side project. Investors include Kae Capital, W Health Ventures, HealthQuad, and British International Investment, with no IPO or public listing to date.
- Who is Wysa's biggest competitor?
- Woebot Health was Wysa's closest direct peer but shut down its consumer chatbot app on June 30, 2025 due to LLM disruption and FDA cost. UnitedHealth also absorbed rival Sanvello in-house in 2025, showing incumbents can build equivalent tools.
- Has Wysa received FDA approval?
- Wysa holds FDA Breakthrough Device Designation, granted May 12, 2022, for its AI conversational agent targeting chronic musculoskeletal pain plus depression/anxiety. This is a designation that speeds review, not full FDA marketing authorization.
- Why did Wysa acquire April Health and Kins?
- Wysa acquired virtual behavioral health provider April Health in March 2025 and physical therapy company Kins on September 30, 2025, both in reverse-acquisition structures, to embed its AI into licensed clinical care delivery and insurance billing pathways, financial terms undisclosed.
Timeline
- 2025-09-30Wysa acquires Kins, a US physical therapy services company, via reverse acquisition
- 2025-07-02Peer Woebot shuts down consumer chatbot app, citing LLM disruption and FDA cost
- 2025-03-11Wysa acquires virtual behavioral health provider April Health
- 2024-10-10Wysa launches SAFE-LMH multilingual LLM safety evaluation initiative
- 2022-07-18Wysa closes $20M Series B led by HealthQuad and British International Investment
- 2022-05-12Wysa receives FDA Breakthrough Device Designation for AI mental health conversational agent
- 2021-05-21Wysa raises $5.5M Series A led by W Health Ventures
- 2017-08-01Wysa (as Touchkin) raises $1.3M seed round from Kae Capital and angels
- 2015Wysa founded by Jo Aggarwal and Ramakant Vempati as Touchkin eServices side project
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Why Woebot, a pioneering therapy chatbot, shut down (2025-07-02)
- Best Mental Health Apps for Pregnancy & Postpartum (2026) (2026-06-13)
- We're investing in Wysa to help address global mental health demand with AI digital therapeutics (2022-07-18)
- Wysa Acquires Virtual Behavioral Health Provider April Health (2025-03-11)
- Wysa Acquires Kins Physical Therapy (2025-09-30)
- Wysa Receives FDA Breakthrough Device Designation for AI-led Mental Health Conversational Agent (2022-05-12)
- Wysa Launches Multilingual AI Safety Initiative to Evaluate Large Language Models for Mental Health Support (2024-10-10)
- Touchkin Raises $1.3M in Seed Funding from Kae Capital and Others for its Mental Health Chatbot Wysa (2017-08-01)
- Mental health app Wysa raises $5.5M for emotionally intelligent AI (2021-05-21)
- Wysa Stock Price, Funding, Valuation & Financial Statements (2026-02-01)
- Everyday Mental Health (Team)
- Better Employee Mental Health with Clinically Proven AI Support